• 1
    Glazier A, Tutschka PJ, Farmer ER, Santos GW. Graft-versus-host disease in cyclosporin A-treated rats after syngeneic and autologous bone marrow transplantation reconstitution. J Exp Med 1983; 158: 18.
  • 2
    Hess AD, Horwitz LR, Beschorner WE, Santos GW. Development of graft-vs-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation. Development of cytotoxic T-lymphocytes with apparent polyclonal anti-Ia specificity, including autoreactivity. J Exp Med 1985; 161: 718730.
  • 3
    Jones RJ, Hess AD, Mann RB et al. Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 1989; 1: 754757.
  • 4
    Kennedy MJ, Vogelsand GB, Jones RJ et al. Phase I trial of interferon gamma to potentiate cyclosporine-induced graft versus-host disease in women undergoing autologous bone marrow transplantation. J Clin Oncol 1994; 12: 249257.
  • 5
    Sorokin R, Kimura H, Shroder K, Wilson DH, Wilson DB. Cyclosporine-induced autoimmunity. Conditions for expressing disease, requirement for intact thymus and potency estimates of autoimmune lymphocytes in drug-treated rats. J Exp Med 1986; 164: 16151625.
  • 6
    Bryson JS, Jennings CD, Caywood BE, Kaplan AM. Induction of a syngeneic graft-versus-host disease-like syndrome in DBA/2 mice. Transplantation 1989; 48: 10421047.
  • 7
    Osman Y, Watanabe T, Kawachi Y et al. Intermediate TCR cells with self-reactive clones are effector cells which induce graft-versus-host disease in mice. Cell Immunol 1995; 166: 172186.
  • 8
    Wu DY, Goldschneider I. Tolerance to cyclosporin A-induced autologous graft-versus-host disease is mediated by a CD4+CD25+ subset of recent thymic emigrants. J Immunol 2001; 166: 71587164.
  • 9
    Shinozawa T, Beschorner WE, Hess AD. The thymus and prolonged administration of cyclosporine: irreversible immunopathologic changes associated with autologous pseudo-graft-vs-host-disease. Transplantation 1990; 50: 106111.
  • 10
    Bryson JS, Jennings CD, Caywood RI, Kaplan AM. Strain specificity in the induction of syngeneic graft-versus-host disease in mice. Transplantation 1991; 51: 911913.
  • 11
    Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25)Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 11511164.
  • 12
    McElwee KJ, Spiers EM, Oliver RF. In vivo depletion of CD8+ T cells restores hair growth in the DEBR model for alopecia areata. Br J Dermatol 1996; 135: 211217.
  • 13
    Hess AD, Fischer AC, Horwitz L, Bright EC, Laulis MK. Characterization of peripheral autoregulatory mechanisms that prevent development of cyclosporin-induced syngeneic graft-versus-host disease. J Immunol 1994; 153: 400411.
  • 14
    Hoffmann R. The potential role of cytokines and T cells in alopecia areata. J Invest Dermatol Symp Proc 1999; 4: 235238.
  • 15
    Perret C, Weisner-Menzel L, Happle R. Immunohistochemical analysis of the T-cell subsets in the peribulbar and intrabulbar infiltrates of alopecia areata. Acta Derm Venereol 1984; 64: 2640.
  • 16
    Gilhar A, Shalaginov R, Assy B, Serafimovich S, Kalish RS. Alopecia areata is a T-lymphocyte mediated autoimmune disease: lesional human T-lymphocytes transfer alopecia areata to human skin grafts on SCID mice. J Invest Dermatol Symp Proc 1999; 4: 207210.
  • 17
    Akiba H, Kehren J, Ducluzeau MT et al. Skin inflammation during contact hypersensitivity is mediated by early recruitment of CD8+ T cytotoxic 1 cells inducing keratinocyte apoptosis. J Immunol 2002; 168: 30793087.
  • 18
    Gilhar A, Landau M, Assy B et al. Transfer of alopecia areata in the human scalp graft/Prkdcscid (SCID) mouse system is characterized by a TH1 response. Clin Immunol 2003; 106: 181187.
  • 19
    McElwee K, Freyschmidt-Paul P, Ziegler A, Happle R, Hoffmann R. Genetic susceptibility and severity of alopecia areata in human and animal models. Eur J Dermatol 2001; 11: 1116.
  • 20
    Freyschmidt-Paul P, Ziegler A, McElwee KJ et al. Treatment of alopecia areata in C3H/HeJ mice with the topical immunosuppressant FK506 (Tacrolimus). Eur J Dermatol 2001; 11: 405409.
  • 21
    Ferrara LM, Teshima T. Understanding the alloresponse: new approach to graft-versus-host disease prevention. Semin Hematol 2002; 39: 1522.
  • 22
    Rappeport J, Mihm M, Reinherz E, Lopanski S, Parkman R. Acute graft-versus-host disease in recipients of bone-marrow transplants from identical twin donors. Lancet 1979; 2: 717720.
  • 23
    Hess AD, Thoburn CJ. Immunobiology and immunotherapeutic implications of syngeneic/autologous graft-versus-host disease. Immunol Rev 1997; 157: 111123.
  • 24
    Barendrecht MM, Tervaert JW, Van Breda Vriesman PJ, Damoiseaux JG. Susceptibility to cyclosporin A-induced autoimmunity: strain differences in relation to autoregulatory T cells. J Autoimmune 2002; 18: 3948.
  • 25
    Urdahl KB, Pardoll DM, Jenkins MK. Cyclosporin A inhibits positive selection and delays negative selection in αβ TCR transgenic mice. J Immunol 1994; 152: 28532859.
  • 26
    Severino ME, Laulis MK, Horwitz LR, Hess AD. Cyclosporine preferentially inhibits clonal deletion of CD8 positive T-cells with an MHC class II restricted autoreactive T-cell receptor. Transplant Proc 1993; 25: 520523.
  • 27
    Teshima T, Reddy P, Liu C, Williams D, Cooke KR, Ferrara LM. Impaired thymic negative selection causes autoimmune graft-versus-host disease. Blood 2003; 102: 429435.
  • 28
    Dubois B, Chapat L, Goubier A, Kaiserlian D. CD4+CD25+ T cells as key regulators of immune responses. Eur J Dermatol 2003; 13: 111116.
  • 29
    Jiang S, Lechler RI. Regulatory T cells in the control of transplantation tolerance and autoimmunity. Am J Transplant 2003; 3: 516524.